Chronic Lymphocytic Leukemia Clinical Trial

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary

Additional active agents are needed to further improve the treatment of patients with leukemia-cll/" >CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL

View Full Description

Full Description

Upon determination of eligibility, patients will receive:

Arsenic Trioxide

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

Histologically proven B-cell CLL/SLL.
Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
Must have progressive CLL/SLL
Measurable or evaluable disease
ECOG performance status 0, 1, or 2
Age > 18 years.
Patients with cytopenias caused by bone marrow involvement are eligible
All patients must give written informed consent prior to entering this study.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

Unstable active infection on the basis of neutropenia
Previous severe opportunistic infections
Severe immune mediated anemia or thrombocytopenia
Serious underlying medical conditions
Brain metastases or meningeal involvement
History of other neoplasms
Significant underlying heart dysfunction
Women who are pregnant or

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 2

Estimated Enrollment:

41

Study ID:

NCT00193518

Recruitment Status:

Completed

Sponsor:

SCRI Development Innovations, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Tennessee Oncology, PLLC
Nashville Tennessee, 37023, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 2

Estimated Enrollment:

41

Study ID:

NCT00193518

Recruitment Status:

Completed

Sponsor:


SCRI Development Innovations, LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider